Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +91.15%. A quarter ago, it was expected that this company would post a loss of $0.98 per share when it actually produced a loss of $1.1, delivering a surprise of -12.24%.Over the last four quarters, the company has ...